NCT06529445已完成1 期
Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 84
- 试验地点
- 1
- 主要终点
- Peak time(Tmax)
研究概览
简要总结
This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate Food effect and Relative bioavailability of VC004 Capsules in healthy subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able and willing to give written informed consent before study, and fully understand the study content, process and possible adverse reactions;
- •Able to complete the study in compliance with the protocol;
- •Subject (including partner) is willing to voluntarily take effective contraceptive measures from screening through 6 months after the last dose of study drug (see Appendix 5 for details);
- •Male and female subjects between the ages of 18 and 45 years, inclusive;
- •At least 50.0kg for male subjects, 45.0kg for female subjects, with a Body Mass Index (BMI= Weight/Height2) between 19.0-26.0 kg/m2, inclusive;
排除标准
- •More than 5 cigarettes per day on average within 3 months prior to screening;
- •with a history of allergies, including medication, food, mites, etc., or those known to be potentially allergic to drugs of the same class as the study drug;
- •History of drug and/or alcohol abuse (alcoholism defined as: drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); history of drug abuse or or have used drugs within the past five years;
- •Donation or loss of a significant volume of blood (> 400 mL) within 3 months prior to screening;
- •History of difficulties in swallowing or any history of gastrointestinal(such as reflux esophagitis, peptic ulcer, chronic diarrhea, chronic constipation), liver, kidney disease (whether cured or not) or surgery that affects drug absorption or excretion within 6 months prior to screening;
- •Those who Have taken strong inhibitors and / or inducers of liver metabolic enzymes (CYP1A2, 2A6, 2b6, 2c8, 2c19, 3A4 and 3A5) within 28 days prior to screening :strong inhibitors of liver metabolic enzymes such as ciprofloxacin, clopidogrel, itraconazole, ketoconazole, ritonavir, oleandomycin etc., strong inducers of liver metabolic enzymes such as rifampicin, carbamazepine, phenytoin sodium, St. John's wort, etc; Those who Have taken inhibitors and inducers of P-gp, MRPs, BCRP, OATP and other transporters and transporters within 28 days prior to screening; See Appendix 5 for details;
- •Intake of any prescription drugs, over-the-counter drugs, vitamin or herbal medicine within 14 days prior to screening;
- •Taking foods that affect CYP3A4 metabolism, such as grapefruit or drinks containing grapefruit within 2 weeks prior to screening, or taking high-intensity physical exercises (such as strength training, aerobic training and football playing) within 7 days prior to screening, or any other factors that affect drug absorption, distribution, metabolism and excretion;
- •Participated in other clinical trials within 3 months before screening (if the subject withdraws from the study before treatment, i.e. has not been randomized or received treatment, he or she can be enrolled in the study);
- •Those who cannot tolerate high-fat meals or have special requirements for diet and cannot accept unified diet；
- •A clinically significant vital signs abnormality during screening (body temperature (axillary temperature) < 36.0 ℃ or > 37.0 ℃; Pulse < 60bpm or > 100bpm; Systolic blood pressure <90mmhg or ≥ 140mmHg, diastolic blood pressure <60mmhg or ≥ 90mmHg);
- •A clinically significant 12-lead ECG abnormality;
- •Positive test results of blood pregnancy or is lactating for female subjects;
- •Any clinically significant abnormalities/findings in laboratory tests, or any clinically significant disease including but not limited to gastrointestinal, renal, hepatic, neurological system, blood, endocrine, tumor, lung, immune, mental, or cardiovascular and cerebrovascular diseases;
- •Positive test results for viral hepatitis (including hepatitis B and C), HIV antibody or syphilis antibody during screening;
- •Acute illness or concomitant medication from screening to the first dosing of study medication;
- •Consumption of chocolate or any food or beverages containing caffeine or (rich containing) xanthine within 24 h prior to screening;
- •Consumption of any product containing alcohol within 24 h prior to screening, or positive results from a screen for alcohol;
- •Positive results from a screen for urine drug test;
- •Cannot tolerate venipuncture and have a history of needle and blood sickness;
- •Subjects with Lactose intolerant;
- •Subjects were vaccinated within 4 weeks prior to screening, or planned to be vaccinated during the trial;
- •Any condition which in the opinion of Investigator is not suitable for subjects to participate in the study.
研究组 & 干预措施
High Dose VC004 group
Experimental
干预措施: High Dose VC004 Capsules (Drug)
Median Dose VC004 group
Experimental
干预措施: Median Dose VC004 Capsules (Drug)
Low Dose VC004 group
Experimental
干预措施: Low Dose VC004 Capsules (Drug)
结局指标
主要结局
Peak time(Tmax)
时间窗: Day1-Day7
Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC）
时间窗: Day1-Day7
Maximum Observed Plasma Concentration (Cmax)
时间窗: Day1-Day7
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy ParticipantsHealthyNCT03066687Janssen Research & Development, LLC16
已完成
1 期
Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With RitonavirHCV InfectionNCT00909311Abbott8
已完成
1 期
A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147Focal Segmental Glomerulosclerosis (FSGS)NCT05955872Vertex Pharmaceuticals Incorporated21
已完成
1 期
Food Effects on the Relative Bioavailability of Different Dosages of RisedronatePostmenopausalNon-lactatingSurgically SterileNCT00717145Warner Chilcott94
已完成
1 期
A Study of JNJ-70033093 (Milvexian) in Healthy Adult ParticipantsHealthyNCT04844424Janssen Research & Development, LLC115